Miguel Arturo Pavlovsky

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan et al. · The Lancet Oncology · 2015 · 408 citations

Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia, Medicine +9

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Graeme Fraser, Paula Cramer, Rodrigo Santucci Alves da Silva et al. · Leukemia · 2018 · 116 citations · Full text

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Thomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò et al. · Leukemia · 2021 · 94 citations · Full text

Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study

Vânia Hungria, Carlos Chiattone, Miguel Arturo Pavlovsky et al. · Journal of Global Oncology · 2019 · 75 citations · Full text

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

Jennifer R. Brown, John F. Seymour, Wojciech Jurczak et al. · New England Journal of Medicine · 2025 · 65 citations